Vertex Pharmaceuticals (VRTX) Short-term Investments (2009 - 2026)

Vertex Pharmaceuticals' Short-term Investments history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• In Q1 2026, Short-term Investments rose 14.89% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 14.89% YoY), while the FY2025 annual figure was $1.5 billion, down 1.49% from the prior year.
• Short-term Investments for Q1 2026 stood at $1.8 billion, up from $1.5 billion in the prior quarter.
• The five-year high for Short-term Investments was $1.8 billion in Q1 2026, with the low at $274.5 million in Q4 2022.
• The 5-year median for Short-term Investments is $1.1 billion (2023), against an average of $1.1 billion.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments tumbled 62.39% in 2022, then surged 209.36% in 2023.
• Vertex Pharmaceuticals' Short-term Investments stood at $274.5 million in 2022, then soared by 209.36% to $849.2 million in 2023, then jumped by 82.09% to $1.5 billion in 2024, then retreated by 1.49% to $1.5 billion in 2025, then gained by 15.13% to $1.8 billion in 2026.
• Business Quant data shows VRTX's Short-term Investments at $1.8 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.3 billion in Q3 2025.